ArticlePloS one2026
In-silico identification and optimization of MMP-9 inhibitors for cerebral ischemia using structure based virtual screening, MD simulation, and binding free energy calculations.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia is a leading cause of disability and mortality due to the limited therapies of neuroprotection. Matrix metalloproteinase-9 (MMP-9) plays a major role in cerebral ischemia as it breaks down the components of extracellular matrix, which maintains the tissue structure and integrity, making MMP-9 a potential target for therapeutic intervention. The existing inhibitors show poor pharmacokinetics so in this study, we have designed a comprehensive pipeline which combines structure-based pharmacophore modelling, and MD simulation to identify selective MMP-9 inhibitors. We performed virtual screening and then hits were processed by molecular docking, ADMET analysis. Our results identify hit compound CHEMBL3990662 whose stability with MMP-9 was confirmed by MD Simulation. Further the binding free energy was calculated by employing MMGBSA and MMPBSA methods. This study highlights the potential of computational pipeline in the development of MMP-9 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.